Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback